)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
NeuroSense Therapeutics
NeuroSense Therapeutics (NRSN) investor relations material
NeuroSense Therapeutics Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary30 Jul, 2026
Company overview and business model
Clinical-stage biotechnology company focused on neurodegenerative diseases: ALS, Alzheimer's, and Parkinson's.
Lead candidate PrimeC is an oral, fixed-dose combination of ciprofloxacin and celecoxib targeting ALS via multiple disease pathways.
PrimeC has orphan drug designation from FDA and EMA, and SME status from EMA.
Pipeline includes additional candidates for Alzheimer's (CogniC) and Parkinson's (StabiliC), using a similar combined product strategy.
Strong patent estate with protection for PrimeC and related formulations through at least 2042, plus expected orphan drug exclusivity.
Financial performance and metrics
As of July 29, 2026, market value of outstanding equity held by non-affiliates was ~$24.1 million.
Cash position as of December 31, 2025, was $166,000 (actual), $2.7 million (pro forma), and $6.4 million (pro forma as adjusted for recent offerings).
Net tangible book value per share after the offering is estimated at $0.10, with immediate dilution of $0.38 per share to new investors.
Company has a history of recurring losses, equity deficit, negative working capital, and negative cash flows, raising substantial doubt about its ability to continue as a going concern.
Use of proceeds and capital allocation
Net proceeds will be used to advance clinical development of PrimeC for ALS, support IND applications for CogniC (AD) and StabiliC (PD), fund future R&D, and for working capital and general corporate purposes.
Management retains broad discretion over allocation of proceeds.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from NeuroSense Therapeutics
- PrimeC showed unprecedented survival and disease-modifying effects in ALS, advancing to Phase 3.NRSN
Corporate presentation - PrimeC slowed ALS progression by 32.8% and improved survival by 65% in Phase 2b trials.NRSNCorporate presentation
- PrimeC slowed ALS progression by 32.8% and improved survival, advancing to Phase 3 in 2026.NRSNCorporate presentation
- PrimeC showed significant ALS survival benefits as late-stage trials and regulatory steps advance.NRSNQ4 2025
- PrimeC slowed ALS progression by 32.8% over 18 months and advances to Phase 3 in 2026.NRSNCorporate presentation
- PrimeC slowed ALS progression by 32.8% and improved survival by 58% in Phase 2b trials.NRSNCorporate presentation
- Biotech seeks $150M to advance ALS drug PrimeC amid ongoing losses and regional risks.NRSNRegistration Filing
- Advancing ALS therapy to Phase III, with recent financings and ongoing Nasdaq compliance risks.NRSNRegistration Filing
- ALS drug developer registers shares for resale amid financial and geopolitical challenges.NRSNRegistration Filing
Next NeuroSense Therapeutics earnings date
Q2 20263 Nov, 2026
NeuroSense Therapeutics
Next NeuroSense Therapeutics earnings date
Q2 20263 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
NeuroSense Therapeutics Ltd is a biotechnology company focused on developing treatments for neurodegenerative diseases. The company specializes in multi-target drug therapies designed to address conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and Alzheimer’s disease. The company is headquartered in Herzliya, Israel, and its shares are listed on the NASDAQ.